[FOLD] Amicus Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.99 Change: 0.46 (10.15%)
Ext. hours: Change: 0 (0%)

chart FOLD

Refresh chart

Strongest Trends Summary For FOLD

FOLD is in the long-term up 367% in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company?s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha g

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-40.12% ROE-74.29% ROI-61.43%
Current Ratio7.19 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.06 M Cash From Investing Activities21.66 M Cash From Operating Activities-20.98 M Gross Profit
Net Profit-24.29 M Operating Profit-24.06 M Total Assets192.62 M Total Current Assets151.25 M
Total Current Liabilities21.02 M Total Debt14.4 M Total Liabilities88.61 M Total Revenue
Technical Data
High 52 week17.09 Low 52 week8.38 Last close12.25 Last change-2.62%
RSI35.01 Average true range0.62 Beta1.18 Volume3.52 M
Simple moving average 20 days-6.53% Simple moving average 50 days-8.64% Simple moving average 200 days0.24%
Performance Data
Performance Week-3.77% Performance Month-4.82% Performance Quart7.27% Performance Half13.64%
Performance Year-23.72% Performance Year-to-date27.87% Volatility daily2.42% Volatility weekly5.4%
Volatility monthly11.07% Volatility yearly38.34% Relative Volume222.44% Average Volume3.04 M
New High New Low

News

2020-05-21 14:25:26 | Edited Transcript of FOLD earnings conference call or presentation 7-May-20 12:30pm GMT

2020-05-19 09:47:32 | Billionaire Steven Cohen Bets Big on These 3 Stocks

2020-05-10 09:50:50 | Analysts Are Updating Their Amicus Therapeutics, Inc. NASDAQ:FOLD Estimates After Its First-Quarter Results

2020-05-09 13:31:04 | Amicus Therapeutics Inc FOLD Q1 2020 Earnings Call Transcript

2020-05-08 11:46:06 | 7 “Strong Buy” Healthcare Stocks to Buy Now

2020-05-08 07:00:10 | Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders

2020-05-07 09:25:01 | Amicus Therapeutics FOLD Reports Q1 Loss, Tops Revenue Estimates

2020-05-07 07:00:10 | Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

2020-05-06 07:00:10 | UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

2020-05-05 07:00:10 | Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

2020-04-30 12:33:04 | Will Amicus Therapeutics FOLD Report Negative Earnings Next Week? What You Should Know

2020-04-24 07:00:10 | Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020

2020-04-13 08:42:10 | Is Amicus Therapeutics, Inc. NASDAQ:FOLD A Volatile Stock?

2020-04-01 11:30:03 | Amicus Therapeutics FOLD Up 1.1% Since Last Earnings Report: Can It Continue?

2020-03-28 20:38:10 | Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. FOLD

2020-03-23 07:00:10 | Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees

2020-03-22 15:58:43 | Edited Transcript of FOLD earnings conference call or presentation 2-Mar-20 1:30pm GMT

2020-03-05 07:00:10 | Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia

2020-03-04 07:20:02 | Amicus Therapeutics, Inc. Yearly Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

2020-03-03 14:20:42 | Amicus set to unveil $25M global research and gene therapy center in University City Photo gallery

2020-03-03 09:38:02 | Amicus' FOLD Q4 Earnings Miss Estimates, Sales Surpass

2020-03-02 08:25:01 | Amicus Therapeutics FOLD Reports Q4 Loss, Tops Revenue Estimates

2020-03-02 07:00:10 | Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates

2020-02-26 07:00:10 | Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference

2020-02-24 12:30:05 | Amicus Therapeutics FOLD May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2020-02-19 07:00:10 | Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020

2020-02-17 07:43:24 | Our Take On Amicus Therapeutics, Inc.'s NASDAQ:FOLD CEO Salary

2020-02-07 07:00:10 | Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020

2020-01-13 07:00:10 | Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance

2020-01-10 11:43:15 | 2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. FOLD

2020-01-09 07:00:10 | Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance

2020-01-08 10:04:03 | Amicus FOLD Provides Updates on AT-GAA for Pompe Disease

2020-01-07 07:00:10 | Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease

2020-01-03 09:41:02 | Amicus Progresses on Pipeline Development Amid Competition

2020-01-02 08:04:36 | If You Had Bought Amicus Therapeutics NASDAQ:FOLD Stock Three Years Ago, You Could Pocket A 73% Gain Today

2019-12-11 11:30:04 | Why Is Amicus Therapeutics FOLD Up 6% Since Last Earnings Report?

2019-12-05 22:53:02 | Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. FOLD Too Early

2019-12-04 09:28:02 | Amicus Therapeutics, Inc. FOLD Shares March Higher, Can It Continue?

2019-11-20 10:09:16 | Co-working space takes aim at Lake Nona

2019-11-19 15:03:08 | How to Find Cheap Buy-Ranked Stocks Trading Under $10

2019-11-18 09:24:59 | Is Amicus Therapeutics NASDAQ:FOLD A Risky Investment?

2019-11-12 18:51:32 | Edited Transcript of FOLD earnings conference call or presentation 11-Nov-19 1:30pm GMT

2019-11-12 09:52:02 | Amicus' FOLD Shares Rise on Q3 Earnings & Revenue Beat

2019-11-12 09:33:02 | Company News For Nov 12, 2019

2019-11-12 09:25:00 | Done deal: Tavistock sells land to New Jersey biotech firm

2019-11-11 08:15:01 | Amicus Therapeutics FOLD Reports Q3 Loss, Tops Revenue Estimates

2019-11-11 07:00:00 | Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates

2019-11-07 11:41:16 | Bet on This Biotech Before Earnings

2019-11-07 11:15:04 | Cronos CRON to Report Q3 Earnings: What's in the Cards?

2019-11-05 11:50:04 | CannTrust CTST to Report Q3 Earnings: What's in Store?